Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

January 1, 2023

Conditions
Hand, Foot, and Mouth Disease
Interventions
DRUG

EPs® 7630

EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \>12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.

Trial Locations (1)

34517

Istinye University Medicine Faculty Hospital, Esenyurt

All Listed Sponsors
collaborator

Abdi Ibrahim Ilac San. ve Tic A.S.

INDUSTRY

lead

Eskisehir Osmangazi University

OTHER

NCT06353477 - Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option | Biotech Hunter | Biotech Hunter